Cite
Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY).
MLA
Aokage, Keiju, et al. “Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY).” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, Oct. 2024. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-1561.
APA
Aokage, K., Koyama, S., Kumagai, S., Nomura, K., Shimada, Y., Yoh, K., Wakabayashi, M., Fukutani, M., Furuya, H., Miyoshi, T., Tane, K., Samejima, J., Taki, T., Hayashi, T., Matsubayashi, J., Ishii, G., Nishikawa, H., Ikeda, N., & Tsuboi, M. (2024). Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY). Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-24-1561
Chicago
Aokage, Keiju, Shohei Koyama, Shogo Kumagai, Kotaro Nomura, Yoshihisa Shimada, Kiyotaka Yoh, Masashi Wakabayashi, et al. 2024. “Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY).” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, October. doi:10.1158/1078-0432.CCR-24-1561.